Information Provided By: 
Fly News Breaks for August 31, 2017
CORT
Aug 31, 2017 | 06:45 EDT
Stifel analyst Adam Walsh started Corcept Therapeutics with a Buy rating and $20 price target. The analyst sees "strong" revenue growth in the company's Cushing's syndrome franchise over the next several years. He;s also optimistic that the Corcept's second-generation compound '134 could more than double the Korlym market potential.
News For CORT From the Last 2 Days
